Monte Rosa Valuation
| GLUE Stock | USD 19.55 0.65 3.44% |
At this time, the firm appears to be undervalued. Monte Rosa Therapeutics secures a last-minute Real Value of $25.24 per share. The latest price of the firm is $19.55. Our model forecasts the value of Monte Rosa Therapeutics from analyzing the firm fundamentals such as Return On Equity of 0.0928, profit margin of 0.12 %, and Current Valuation of 1.14 B as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Monte Rosa's valuation include:
Undervalued
Today
Please note that Monte Rosa's price fluctuation is somewhat reliable at this time. Calculation of the real value of Monte Rosa Therapeutics is based on 3 months time horizon. Increasing Monte Rosa's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Monte stock is determined by what a typical buyer is willing to pay for full or partial control of Monte Rosa Therapeutics. Since Monte Rosa is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Monte Stock. However, Monte Rosa's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 19.55 | Real 25.24 | Target 33.8 | Hype 21.03 |
The real value of Monte Stock, also known as its intrinsic value, is the underlying worth of Monte Rosa Therapeutics Company, which is reflected in its stock price. It is based on Monte Rosa's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Monte Rosa's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Monte Rosa Therapeutics helps investors to forecast how Monte stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Monte Rosa more accurately as focusing exclusively on Monte Rosa's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Monte Rosa's intrinsic value based on its ongoing forecasts of Monte Rosa's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Monte Rosa's closest peers. If more than one evaluation category is relevant for Monte Rosa we suggest using both methods to arrive at a better estimate.
Monte Rosa Cash |
|
Monte Rosa Total Value Analysis
Monte Rosa Therapeutics is currently anticipated to have valuation of 1.14 B with market capitalization of 1.49 B, debt of 42.72 M, and cash on hands of 294.14 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Monte Rosa fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.14 B | 1.49 B | 42.72 M | 294.14 M |
Monte Rosa Investor Information
About 94.0% of the company shares are owned by institutional investors. The company had not issued any dividends in recent years. Based on the key measurements obtained from Monte Rosa's financial statements, Monte Rosa Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Monte Rosa Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Monte Rosa has an asset utilization ratio of 17.24 percent. This indicates that the Company is making $0.17 for each dollar of assets. An increasing asset utilization means that Monte Rosa Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Monte Rosa Profitability Analysis
Based on the key profitability measurements obtained from Monte Rosa's financial statements, Monte Rosa Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Monte Rosa's ability to earn profits and add value for shareholders.Net Loss | First Reported 2020-03-31 | Previous Quarter -12.3 M | Current Value -27.1 M | Quarterly Volatility 18.6 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.71 | 0.8 |
|
|
For Monte Rosa profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Monte Rosa Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Monte Rosa utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Monte Rosa's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Monte Rosa over time as well as its relative position and ranking within its peers.
Monte Rosa Earnings per Share Projection vs Actual
By analyzing Monte Rosa's earnings estimates, investors can diagnose different trends across Monte Rosa's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Monte Rosa Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Monte Rosa Ownership Allocation
Monte Rosa Therapeutics maintains a total of 76.24 Million outstanding shares. The majority of Monte Rosa outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Monte Rosa Therapeutics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Monte Rosa Therapeutics. Please pay attention to any change in the institutional holdings of Monte Rosa as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Monte Rosa Profitability Analysis
The company reported the previous year's revenue of 75.62 M. Net Loss for the year was (72.7 M) with profit before overhead, payroll, taxes, and interest of 50.97 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Monte Rosa's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Monte Rosa and how it compares across the competition.
About Monte Rosa Valuation
The stock valuation mechanism determines Monte Rosa's current worth on a weekly basis. Our valuation model uses a comparative analysis of Monte Rosa. We calculate exposure to Monte Rosa's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Monte Rosa's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 77.6 M | 81.5 M | |
| Pretax Profit Margin | (0.83) | (0.88) | |
| Operating Profit Margin | (0.97) | (1.01) | |
| Net Loss | (0.87) | (0.91) | |
| Gross Profit Margin | 0.80 | 0.71 |
Monte Rosa Growth Indicators
Investing in growth stocks can be very risky. If the company such as Monte Rosa does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 73.9 M | |
| Forward Price Earnings | 10.02 |
Monte Rosa Current Valuation Indicators
Valuation refers to the process of determining the present value of Monte Rosa Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Monte we look at many different elements of the entity such as Monte's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Monte Rosa, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Monte Rosa's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Monte Rosa's worth.Complementary Tools for Monte Stock analysis
When running Monte Rosa's price analysis, check to measure Monte Rosa's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monte Rosa is operating at the current time. Most of Monte Rosa's value examination focuses on studying past and present price action to predict the probability of Monte Rosa's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monte Rosa's price. Additionally, you may evaluate how the addition of Monte Rosa to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |